4.4 Article

Trends in treatment-related deaths (TRDs) in childhood cancer and leukemia over time:: A follow-up of patients included in the childhood cancer registry of the Rhone-Alpes Region in France (ARCERRA)

Journal

PEDIATRIC BLOOD & CANCER
Volume 50, Issue 6, Pages 1213-1220

Publisher

WILEY
DOI: 10.1002/pbc.21506

Keywords

cancer registry; childhood cancer; childhood leukemia; pediatric oncology; transplantation-related death; treatment-related death

Ask authors/readers for more resources

Background. We assessed the number and causes of treatment-related deaths (TRDs) in childhood cancer over time and correlated them with adherence to therapeutic guidelines. Procedure. We compared two cohorts of children of the Childhood Cancer Registry of the Rhone-Alpes Region: Cohort I (1987-1992, 909 patients) and Cohort II (1996-1999, 648 patients). Results. In all cancers together, 75 TRDs were reported in Cohort I and 24 in Cohort II (P=0.001). Cumulative incidence at 5 years declined from 7.9% to 4.1%, and overall survival (OS) increased from 71.0% to 77.2%. TRDs declined by nearly 10-fold in patients with solid malignant tumors (P=0.02) and central nervous system tumors (P=0.001), but OS improved for patients with solid malignant tumors only (P=0.01). No difference was observed in treatment- and transplantation-related deaths in patients with acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML), but OS was better in patients with AML (P=0.02). Between the two cohorts, transplantation-related mortality did not decrease and was higher at 5 years in patients with ALL who received unrelated-matched donor transplants (41.3%) than in those receiving sibling-matched donor transplants (18.7%). OS improved in the respective transplant groups (37.0% and 64.2%). Severe graft-versus-host disease was also observed among patients with ALL (P=0.036). The decrease in TRDs was correlated with compliance to therapeutic guidelines. Conclusion. Although mortality declined, improved adherence to therapeutic guidelines and more restricted indications of allograft are needed to preclude further treatment- and transplantation-related deaths, particularly among those with leukemia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available